Background
==========

Subclinical hypothyroidism (SH), which refers to the status of mild elevation of thyroid-stimulating hormone (TSH) in patients with normal serum thyroxine levels, is the most common thyroid disorder, with a prevalence of 3.8--10% in adult populations \[[@b1-medscimonit-20-1432]--[@b4-medscimonit-20-1432]\]. The prevalence of SH rises with age, and varies between sexes and populations \[[@b5-medscimonit-20-1432],[@b6-medscimonit-20-1432]\]. Although the relationships between SH and lipid profile have been reported in several studies, the results are conflicting. Cross-sectional studies on 7000 consecutive patients in Austria and 1423 females in Australia found no significant differences in serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) \[[@b7-medscimonit-20-1432],[@b8-medscimonit-20-1432]\]. On the other hand, many studies reported disparate results. Several studies found serum LDL-C levels increased in SH patients \[[@b9-medscimonit-20-1432]--[@b14-medscimonit-20-1432]\], some of them found higher serum TC levels in SH patients \[[@b9-medscimonit-20-1432]--[@b12-medscimonit-20-1432]\], and other studies found lower serum TC level \[[@b15-medscimonit-20-1432],[@b16-medscimonit-20-1432]\]. Contradictory results were also reported in the alteration of serum HDL-C and TG levels under SH \[[@b13-medscimonit-20-1432],[@b15-medscimonit-20-1432]--[@b18-medscimonit-20-1432]\].

Abnormal lipid profile has been established as a risk factor of coronary heart disease (CHD). To prevent CHD in SH patients, it is important to investigate the association between SH and lipid profile. Since the results of lipid profiles alteration in SH patients were disparate in previous studies, we attempted to form a conclusion about the alteration of each parameter of lipid profiles under SH. Therefore, we reviewed previous studies and performed a meta-analysis to answer this question.

Material and Methods
====================

Data sources and search strategy
--------------------------------

We searched the PubMed, Cochrane Library, and China National Knowledge Infrastructure (CNKI) database for studies in humans that reported relationships between SH and lipid profiles or at least 1 parameter of lipid profiles (TC, LDL-C, HDL-C, and TG). Google Scholar was then used to search for studies that were not included in PubMed, CNKI, or Cochrane Library. We also searched PQDT (ProQuest Theses and Dissertations) and CDMD (Chinese Doctoral Dissertations and Master's Theses full-text database) to find relevant unpublished data. Because the standardized diagnostic for SH and sensitive TSH assay were applied in the 1990s \[[@b19-medscimonit-20-1432],[@b20-medscimonit-20-1432]\], we limited the publication date from January 1990 to January 2014. "Subclinical hypothyroidism", "lipid profile", "TC", "LDL-C", "HDL-C", "TG", and "cholesterol" were used as key words in the search. To avoid missing any potential articles, we also used relevant words as key words, such as "thyroid disease", "thyroid disorder", "thyroid dysfunction", "hypothyroidism", "dysthyroidism", "thyroid hormone", "TSH", "thyrotropin", and "dyslipidemia".

Selection criteria
------------------

Two investigators reviewed the articles independently. To avoid repeated selection, if 2 or more articles that studied the same population were published within 2 years by the same research group, only the article with the largest sample size would be included. The included articles should provide full text, and describe their study populations, and diagnostic standard for SH, and measured at least 1 of 4 lipid profile parameters in SH and euthyroidism (EU) groups. The reference range of TSH was unclear, and several studies suggested different TSH upper limit cutoffs ranging from 2.5 to 5.0 μIU/L \[[@b21-medscimonit-20-1432]--[@b25-medscimonit-20-1432]\]. Since there were no clear standards, we did not set the cutoff value of TSH to define SH, and instead performed a meta-regression based on TSH cutoff values. Considering that most patients with increased TSH were subclinical but did not have overt hypothyroidism \[[@b26-medscimonit-20-1432]\], we also included 3 studies which measured TSH without a thyroxine measurement \[[@b27-medscimonit-20-1432]--[@b29-medscimonit-20-1432]\], and performed a meta-regression to assess the effects; this strategy was used in a previous article \[[@b30-medscimonit-20-1432]\].

Quality assessment and data extraction
--------------------------------------

We assessed the quality of articles by using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklists for cohort, case-control, or cross-sectional studies, depending on the design of studies \[[@b31-medscimonit-20-1432]\]. Although those checklists were initially designed to improve the quality of observation studies, they have been used as quality assessment tools in previous studies \[[@b32-medscimonit-20-1432],[@b33-medscimonit-20-1432]\]. All checklists contained 22 main items, and 2 investigators gave scores of 0 or 1 for each item for all included articles. Five of the main items had sub-items, and those sub-items would also be scored 0 or 1, and then averaged as the score of the main items. The score of the 22 main items would be summed as the STROBE scores to assess the articles. Disagreement on STROBE score was resolved by a group discussion of the investigators.

Data were extracted by 1 investigator and double-checked by another. The following information was extracted from each included article: author, study design, match strategy, year of publication, TSH cutoff value to define SH, characteristics of study populations (sample source, sample size, sex ratios, mean age, and race), mean value and standard deviation of serum TC, LDL-C, HDL-C, and TG levels in both SH and EU groups.

Data analysis
-------------

Units of lipid profile parameters in all included articles were measured in either mmol/L or mg/dL. We converted units of cholesterol (TC, LDL-C, and HDL-C) and TG from mmol/L into mg/dL by multiplying by 38.67 and 88.57, respectively \[[@b34-medscimonit-20-1432],[@b35-medscimonit-20-1432]\]. For each parameter of lipid profiles, summary estimates of weighted mean difference (WMD) and 95% confidence interval (CI) were obtained with a random effects model. The variation across studies attributable to heterogeneity beyond chance was estimated with the *I^2^* heterogeneity test \[[@b36-medscimonit-20-1432]\], where a value greater than 50% may be considered substantial heterogeneity \[[@b37-medscimonit-20-1432]\]. To determine the possible sources of heterogeneity, we performed meta-regression which included study design, match strategy, TSH cutoff value, whether thyroxine was measured or not, sample size, sex, mean age, and race as variates for each lipid profile parameter, and then performed stratified analysis based on the results of the meta-regression. Finally, we used the Egger test and the Begg test to assess potential publication bias \[[@b38-medscimonit-20-1432],[@b39-medscimonit-20-1432]\]. If any possible bias was found, the trim and fill method would be used to identify those results \[[@b40-medscimonit-20-1432]\]. For all tests, a two-tailed *P* value smaller than 0.05 was considered statistically significant. All statistical analyses were performed in STATA software, version 11.0 (Stata, College Station, Texas, USA).

Role of the funding source
--------------------------

This study was supported by the National Natural Science Foundation of China (No. 81102127) and Science Project of Shenzhen (No. 201202103). The funding source had no role in the study design, data collection, data analysis, or writing of the report.

Results
=======

Study selection and quality of studies
--------------------------------------

We identified 2084 studies and excluded 1963 studies that were unrelated to the association between SH and lipid profile. Then, 73 studies were excluded due to lack of diagnostic code to define SH, and 31 studies were excluded due to special selection criteria for participants, or lack of data about sample sizes or lipid profiles. Of the 17 prospective studies which met our criteria, 2 studies \[[@b10-medscimonit-20-1432],[@b12-medscimonit-20-1432]\] published by the same research group may have used repeated data, so we only included the one with the larger sample size \[[@b10-medscimonit-20-1432]\]. During the selection process, we failed to make contact with the authors to obtain the necessary data for 1 article which was carried out in Colorado, USA \[[@b41-medscimonit-20-1432]\]. Finally, 16 studies were included in our analysis ([Figure 1](#f1-medscimonit-20-1432){ref-type="fig"}). Those studies were carried out in 12 countries and included a total of 41 931 adults, among whom 4526 were identified as SH patients and 37405 as having a status of EU. All studies were published in English between 2000 and 2013. Thirteen studies were cross-sectional studies; another 3 were cohort studies which reported lipid profile as baseline of participants before L-T4 or thyroxine treatment. Four studies applied sex-age individual match strategy and 4 studies applied the frequency match strategy. One study included 1 patient with radioiodine therapy history \[[@b10-medscimonit-20-1432]\], 1 study included 2 patients who underwent levothyroxine treatment \[[@b27-medscimonit-20-1432]\], and other studies declared no thyroid medication history in SH patients. Fifteen studies measured all 4 parameters of lipid profile, and 1 study only measured TG and HDL-C levels \[[@b42-medscimonit-20-1432]\]. The STROBE scores of the included articles varied from 13 to 20, with a median of 15.5. The TSH cutoff value varied from 3.5 to 6.7 μIU/L with a median of 4.5 μIU/L ([Table 1](#t1-medscimonit-20-1432){ref-type="table"}).

Subclinical hypothyroidism and TC
=================================

Fifteen included studies measured serum TC levels in 40 546 participants. Most studies suggested that there were higher serum TC levels in SH patients compared with EU participants and only 2 studies reported lower levels without statistical significance. In a random effects model, the overall serum TC level in SH patients was significantly higher than in EU participants ([Figure 2A](#f2-medscimonit-20-1432){ref-type="fig"}, WMD=12.17, 95% CI: 7.79--16.54, *P*\<0.001).

Substantial heterogeneity was found between studies (*I^2^*=79.4%, *P*\<0.001). Univariate meta-regression found heterogeneity was not associated with source of participants, mean age, sex ratio, TSH cutoff values, and whether thyroxine was measured. Match strategy was found associated with heterogeneity ([Figure 2B](#f2-medscimonit-20-1432){ref-type="fig"}, *P*=0.001), which reduced the overall heterogeneity *I^2^* to 52.84%. In the multivariate analysis, the combination of match strategy (*P*=0.001) and source of participants (*P*=0.403) reduced the overall *I^2^* to 46.5%. Grouped by match strategy and source of participants, the stratified analysis showed that individual match studies tended to report considerable alterations of TC levels in SH patients with a large confidence interval (WMD=32.58, 95% CI: 24.81--40.34); in contrast, studies with no match tended to provide conservative results with a much smaller confidence interval (WMD=6.72, 95% CI: 3.30--10.14).

Subclinical hypothyroidism and LDL-C
------------------------------------

Fifteen included studies measured serum TC levels in 39 131 participants. Nine of these studies reported significantly higher LDL-C levels in SH patients when compared with EU participants. Only 1 article reported a slightly decreased LDL-C level in SH patients, which was not statistically significant. In a random effects model, the overall serum LDL-C level in SH patients was significantly higher than in EU participants ([Figure 3A](#f3-medscimonit-20-1432){ref-type="fig"}, WMD=7.01, 95% CI: 3.95--10.05, *P*\<0.001).

Substantial heterogeneity was found between studies (*I^2^*=68.8%, *P*\<0.001). Univariate meta-regression found that match strategy was associated with heterogeneity ([Figure 3B](#f3-medscimonit-20-1432){ref-type="fig"}, *p*=0.002) but other variates were not. The overall heterogeneity *I^2^* was reduced to 38.6% after pull-in effects of match strategy. Multivariate analysis did not find any combination of variates that was associated with heterogeneity. Grouped by match strategy, the stratified analysis found individual match studies reported larger WMD and wider 95% CI (WMD=22.27, 95% CI: 15.07--29.48), compared with no match studies (WMD=6.37, 95% CI: 1.74--4.97). This result was similar to the findings of stratified analysis for TC.

Subclinical hypothyroidism and HDL-C
------------------------------------

The included studies included a total 40 516 participants whose serum HDL-C levels were measured. Three of these studies reported significant lower HDL-C levels in SH patients and 1 reported significant higher level compared with EU participants. In a random effects model, the overall serum HDL-C level in SH patients was lower than in EU participants, but was not statistically significant ([Figure 4](#f4-medscimonit-20-1432){ref-type="fig"}, WMD=--0.50, 95% CI: --1.90--0.89, *P*=0.481). Substantial heterogeneity was found between studies (*I^2^*=73.2%, *P*\<0.001). Meta-regression found no variates that were associated with heterogeneity.

Subclinical hypothyroidism and TG
---------------------------------

Sixteen studies measured serum TG levels. However, 2 studies used the median (and min, max) to describe TG levels \[[@b8-medscimonit-20-1432],[@b16-medscimonit-20-1432]\]. To avoid potential statistical errors, we eliminated those studies in analysis of TG. A random effects model including other 14 studies with 40 420 participants found that the overall serum TG level in SH patients was significant higher than in EU participants ([Figure 5](#f5-medscimonit-20-1432){ref-type="fig"}, WMD=13.19, 95% CI: 4.92--21.46, *P*\<0.001).

A large heterogeneity was found between studies (*I^2^*=90.9%, *p*\<0.001). Univariate meta-regression failed to find any variates associated with heterogeneity. In the multivariate analysis, the model included match strategy (*P*=0.296), source of participant (*P*=0.033), mean age (*P*=0.774), TSH cutoff value (*P*=0.039), and whether measured thyroxine (*P*=0.029) explained 75.7% heterogeneity, which reduced the *I^2^* to 31.48%.

Publication bias
----------------

Egger test and Begg test found no evidence of publication bias for studies on HDL-C (*P*=0.562 for Egger test, *P*=0.753 for Begg test) and TG (*P*=0.343 for Egger test, *P*=0.101 for Begg test). For TC, although the Egger test indicated a potential publication bias (*P*=0.014), the Begg test (*P*=0.235) and the trim and fill method did not confirm this possibility. For LDL-C, both the Egger test and Begg test found publication bias (*P*=0.010 for Egger test, *P*=0.048 for Begg test). However, the trim and fill method found that the conclusions did not significantly change after adjusting for publication bias.

Discussion
==========

Altered lipid profiles, which include elevated levels of TC, TG, LDL-C, and/or a lower level of HDL-C, are thought to confer the risk of cardiovascular disease development \[[@b43-medscimonit-20-1432],[@b44-medscimonit-20-1432]\]. Overt hypothyroidism is associated with an altered lipid profile \[[@b45-medscimonit-20-1432],[@b46-medscimonit-20-1432]\]. However, the relationship between subclinical hypothyroidism and abnormal lipid profile is still unclear. Several cross-sectional studies with large sample sizes were carried out in different countries. The Colorado, USA study showed that SH patients had higher TC and LDL-C level compared with EU populations \[[@b41-medscimonit-20-1432]\]. Another study in Austria did not find those differences \[[@b7-medscimonit-20-1432]\]. An explanation for these conflicting results among these cross-sectional studies is poor control in potential confounding factors, such as sex, age, race, insulin resistance, smoking, and drinking behavior, which may be associated with lipid levels \[[@b47-medscimonit-20-1432]--[@b49-medscimonit-20-1432]\]. An analysis of National Health and Nutrition Examination Survey (NHANES III) samples found higher serum TC and TG levels in SH patients than in EU participants. However, this difference disappeared after adjusting for variables such as sex, age, and race \[[@b50-medscimonit-20-1432]\]. To control for potential confounding factors, many studies applied the sex-age match method. Those studies reported higher TC and LDL-C levels in SH patients compared with EU participants \[[@b9-medscimonit-20-1432],[@b14-medscimonit-20-1432],[@b18-medscimonit-20-1432],[@b27-medscimonit-20-1432],[@b51-medscimonit-20-1432]\].

In the article selection process of our study, we found many cohort studies reported lipid profile as baseline of SH and EU groups before L-thyroxine therapy \[[@b52-medscimonit-20-1432]--[@b54-medscimonit-20-1432]\]. We had to exclude those studies since their selection of participants, such as use the body mass index as part of the inclusion criteria or excluded patients with dyslipidemia, may have led to bias. We also had to exclude a cross-sectional study with a large sample size (the Colorado, USA study) due to lack of the standard deviation data \[[@b41-medscimonit-20-1432]\]. Potential publication bias was found in our study. It is plausible that many small studies with insignificant results might have never been published, which could change the results of this study. Since we only searched articles published in English and Chinese, publication language may be another cause of bias. We found significant heterogeneity between studies, which could also result in publication bias \[[@b55-medscimonit-20-1432]\].

For TC and LDL-C, many previous studies suggested SH patients had higher levels of these parameters compared with EU populations. The mechanisms are still unclear. Alteration to LDL-C receptor levels caused by slight decreases of thyroxine in SH may explain those results \[[@b56-medscimonit-20-1432],[@b57-medscimonit-20-1432]\]. Some studies suggested that TSH, independent of thyroxine, may elevate serum TC and LDL-C levels \[[@b58-medscimonit-20-1432],[@b59-medscimonit-20-1432]\]. Our study found increased levels of serum TC and LDL-C in SH patients compared with EU participants. This result was in accordance with the majority of conclusions of previous studies. For each included study, the trends of alterations in serum TC and LDL-C levels were consistent, and this is reasonable since low-density lipoprotein (LDL) contains 65% total cholesterol \[[@b60-medscimonit-20-1432]\]. Only 2 studies reported an insignificant decrease in TC and LDL-C levels in SH patients \[[@b16-medscimonit-20-1432],[@b27-medscimonit-20-1432]\]. One study explained this result as due to older patients and difference in TSH cutoff values \[[@b16-medscimonit-20-1432]\]. However, we did not find that these 2 studies differed in study design, mean age, sex ratio, or TSH cutoff, compared with other studies. Substantial heterogeneities between studies were found in both TC and LDL-C analysis. Those heterogeneities were reduced after adjusting for match strategy. Sex-age individual match studies found more significant results than no-match studies did, which indicated that individual's sex and age may be associated with serum TC and LDL-C levels; insignificant results from some studies may have been due to differences in the sex and age between EU and SH groups. Hence, we recommend that further studies should consider the effects of sex and age more carefully.

Higher serum TG levels were found in SH patients compared with EU participants in our study. Although this result was consistent with those of many previous studies, it should be treated with caution since there was large and unexplainable heterogeneity between studies. Convictive results on the association between SH and serum TG were not reported, as well as believable mechanisms. Previous studies found that L-T4 therapy could reduce serum TC or LDL-C levels, but in those studies serum TG levels remained consistent after L-T4 therapy \[[@b10-medscimonit-20-1432],[@b54-medscimonit-20-1432]\]. This result indicated that thyroxine may have limited effects on TG. Since the association between SH and TG is still unclear, further studies based on large populations will be required. In the analysis we found several studies used median (and min max) values to describe their data on TG levels; this was reasonable since many studies found that serum TG levels did not match the normal distribution \[[@b61-medscimonit-20-1432]--[@b63-medscimonit-20-1432]\]. On the other hand, some studies that described their TG data by using the mean and standard deviation did not mention any tests for normality. Merging those data may therefore have caused error. To improved data quality, we recommend that further studies, especial those based on small sample sizes, perform normality tests for data on serum TG levels.

We found weak evidence for effects of SH on serum HDL-C level. Although many included studies reported significant alteration of HDL-C levels in SH patients, the overall WMD was insignificant. These results may contribute to the contrasting effects of thyroxine on enzymes related to HDL-C metabolism. Plasma cholesteryl ester transfer protein concentration decreased with slight reductions in serum thyroxine level in SH patients, which may result in higher HDL-C level \[[@b64-medscimonit-20-1432]\]. On the other hand, the activities of hepatic lipase, lecithin cholesterol acyl transferase, and ATP-binding cassette transporter also decreased in SH patients, which may lead to lower HDL-C levels \[[@b64-medscimonit-20-1432],[@b65-medscimonit-20-1432]\]. These 2 contrasting effects neutralized one another, and the HDL-C level may remain stable. Polymorphisms of genes and osteocalcin concentration may effect the metabolism of HDL-C \[[@b66-medscimonit-20-1432],[@b67-medscimonit-20-1432]\], and those factors were not taken into account in most regular epidemiology studies. Another possible reason for the insignificant results was weak control for potential confounding factors in the included studies.

Our study had several limitations. First, all included studies in our analysis were observational studies. Most observational studies did not control potential confounding factors. In our analysis, only a few studies paired participants by sex and age, and even fewer studies adjusted for differences in insulin resistance and smoking and drinking behaviors. Hence, this meta-analysis of observational studies should be interpreted with caution \[[@b68-medscimonit-20-1432]\]. Second, we could not extract information of the degree and duration of subclinical hypothyroidism in patients, which may have significantly affected their lipid profiles. To the best of our knowledge, existing technology cannot adequately measure the degree and duration of SH in patients. Third, we cannot explain the substantial heterogeneity between studies in HDL-C and TG analysis. The heterogeneity may be associated with potential confounding factors that were not mentioned in the studies. Further studies should utilize more rigorous inclusion criteria for participants.

Conclusions
===========

Our analysis suggested that serum TC, LDL-C, and TG levels increased under subclinical hypothyroidism; however, weak evidence suggested subclinical hypothyroidism was associated with serum HDL-C levels. Higher serum TC, LDL-C, and TG levels increased the risk of CHD; therefore, the cardiovascular status of SH patients should be monitored carefully. In the analysis of TC and LDL-C, match strategy was the main source of heterogeneity. Previous studies had limitations regarding the control of potential confounding factors; further studies should take into account those factors.
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###### 

Characteristics of included studies.

  Study, year \[reference\]                                                      Study design                                                      Match strategy          SH/EU sample size, n                                                   Source of samples                      
  ------------------------------------------------------------------------------ ----------------------------------------------------------------- ----------------------- ---------------------------------------------------------------------- -------------------------------------- ------------------
  Vierhapper et al., 2000 \[[@b7-medscimonit-20-1432]\]                          Cross-section                                                     No match                1055/4866                                                              Outpatients from Vienna, Austria       
  Efstathiadou et al., 2001 \[[@b9-medscimonit-20-1432]\]                        Case-control                                                      Individual match        66/75                                                                  Adults living in Ioannina, Greece      
  Caraccio et al., 2002 \[[@b10-medscimonit-20-1432]\]                           Case-control                                                      Individual match        49/33                                                                  Outpatients from Pisa, Italy           
  Cikim et al., 2004 \[[@b27-medscimonit-20-1432]\]                              Cross-section                                                     Frequency match         25/23                                                                  Adults from Istanbul, Turkey           
  Hueston et al., 2004 \[[@b50-medscimonit-20-1432]\]                            Cross-section                                                     No match                215/8013                                                               Residents from USA (NHANES III)        
  Luboshitzky et al., 2004 \[[@b51-medscimonit-20-1432]\]                        Cross-section                                                     Frequency match         44/19                                                                  Outpatients from Haifa, Israel         
  Walsh et al., 2005 \[[@b11-medscimonit-20-1432]\]                              Cross-section                                                     No match                119/1906;30/580 [\*](#tfn1-medscimonit-20-1432){ref-type="table-fn"}   Adults from Busselton, Australia       
  Erem, 2006 \[[@b18-medscimonit-20-1432]\]                                      Cross-section                                                     Individual match        30/20                                                                  Outpatients from Trabzon, Turkey       
  Iqbal et al., 2006 \[[@b13-medscimonit-20-1432]\]                              Case-control                                                      Frequency match         84/145                                                                 Adults from Tromsø, Norway             
  Bell et al., 2007 \[[@b8-medscimonit-20-1432]\]                                Cross-section                                                     No match                81/1271                                                                Adults from Victoria, Australia        
  Torun et al., 2009 \[[@b14-medscimonit-20-1432]\]                              Cross-section                                                     Frequency match         40/40                                                                  Adults from Ankara, Turkey             
  Lai et al., 2011 \[[@b42-medscimonit-20-1432]\]                                Cross-section                                                     No match                102/1283                                                               Adults from Shengyang, China           
  Hernández et al., 2012 \[[@b16-medscimonit-20-1432]\]                          Cross-section                                                     No match                95/65                                                                  Outpatients from Valencia, Spain       
  Moriyama et al., 2012 \[[@b29-medscimonit-20-1432]\]                           Cross-section                                                     No match                137/2315                                                               Adults from Tokyo, Japan               
  Shashikala, 2012 \[[@b28-medscimonit-20-1432]\]                                Cross-section                                                     Individual match        22/25                                                                  Outpatients from Karnataka, India      
  Palacios, 2013 \[[@b17-medscimonit-20-1432]\]                                  Cross-section                                                     No match                2383/17306                                                             Adults from Pamplona, Spain            
  **Mean age (range or SD), y**                                                  **Female, %**                                                     **TSH cutoff, μIU/L**   **Thyroxine measured**                                                 **Lipid profile parameter measured**   **STROBE score**
  --                                                                             --                                                                4.0                     Yes                                                                    TC, HDL-C, LDL-C, TG                   13
  47.8 (12.4)                                                                    90.1                                                              4.5                     Yes                                                                    TC, HDL-C, LDL-C, TG                   17
  33.8 (9.0)                                                                     84.1                                                              3.6                     Yes                                                                    TC, HDL-C, LDL-C, TG                   15
  34.0 (8.8)                                                                     93.8                                                              4.2                     No                                                                     TC, HDL-C, LDL-C, TG                   14
  --                                                                             51.8                                                              6.7                     Yes                                                                    TC, HDL-C, LDL-C, TG                   20
  51.6 (9.7)                                                                     100.0                                                             4.5                     Yes                                                                    TC, HDL-C, LDL-C, TG                   14
  49.7 (16.8); 43.8 (17.4)[\*](#tfn1-medscimonit-20-1432){ref-type="table-fn"}   49.1; 47.0 [\*](#tfn1-medscimonit-20-1432){ref-type="table-fn"}   4.0                     Yes                                                                    TC, HDL-C, LDL-C, TG                   17
  41.3 (13.1)                                                                    78.0                                                              5.0                     Yes                                                                    TC, HDL-C, LDL-C, TG                   13
  61.3 (12.5)                                                                    53.3                                                              3.5                     Yes                                                                    TC, HDL-C, LDL-C, TG                   18
  --                                                                             100.0                                                             4.0                     Yes                                                                    TC, HDL-C, LDL-C, TG                   17
  30.4 (3.7)                                                                     100.0                                                             5.0                     Yes                                                                    TC, HDL-C, LDL-C, TG                   15
  45.1 (13.9)                                                                    --                                                                4.8                     Yes                                                                    HDL-C, TG                              14
  56.7 (13.6)                                                                    100.0                                                             5.0                     Yes                                                                    TC, HDL-C, LDL-C, TG                   16
  51.8                                                                           42.6                                                              5.0                     No                                                                     TC, HDL-C, LDL-C, TG                   15
  35.8 (12.7)                                                                    --                                                                6.0                     No                                                                     TC, HDL-C, LDL-C, TG                   17
  57.1 (19.2)                                                                    62.1                                                              4.43                    Yes                                                                    TC, HDL-C, LDL-C, TG                   16

Only part of participants in Walsh et al. study measured serum HDL-C and LDL-C. The first data was information for TC and TG; the second data was information for HDL-C and LDL-C.
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